The chart solidifies you what you already know: Biotech stocks are off to a blistering start in 2014.
The iShares Nasdaq Biotechnology Index ETF (IBB) is trouncing the S&P 500 through the first three weeks of the year.
Here's the same IBB vs. S&P 500 comparison as above, but looking at the first 20 calendar days of 2013:
The top-performing biotech and drug stocks year to date, according to S&P CapitalIQ:
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;
to send him an email.